The Irish Critical Care Clinical Trials Network supported STARRT-AKI trial, investigating the timing of renal replacement therapy in acute kidney injury, was published in the New England Journal of Medicine in July 2020.
SPRINT-SARI (Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection) is an international, multi-centre, prospective, short period incidence observational study of patients in participating hospitals and intensive care units (ICUs) with severe acute respiratory infection (SARI).
The primary aim of this study is to establish a research response capability for a future epidemic / pandemic through a global SARI observational study. The secondary aim of this study is to investigate the descriptive epidemiology and microbiology profiles of patients with SARI. The tertiary aim of this study is to assess the Ethics, Administrative, Regulatory and Logistic (EARL) barriers to conducting pandemic research on a global level.
SARI continues to be of major relevance to public health worldwide. In the last 10 years there have been multiple SARI outbreaks around the world. The 2009 H1N1 pandemic was estimated to result in more than 200,000 respiratory deaths globally. The World Health Organization (WHO) defines SARI as an acute respiratory infection of recent onset (within 10 days) requiring hospitalisation, manifested by fever (≥38°C) or a history of fever and cough. There is international consensus that it is important to undertake observational studies of patients with SARI as an essential component of pandemic and epidemic research preparedness.
Irish Critical Care-Clinical Trials Network
The HRB funded Irish Critical Care-Clinical Trials Network (ICC-CTN) was established in 2015 to support research being conducted by the Irish Critical Care-Clinical Trials Group (ICC-CTG). The CTN aims to support efforts to conduct high quality clinical trials on the Island of Ireland, based on the opportunity, the science, the feasibility and the ability to enhance the standing of our network locally and internationally. Our approach is to energetically grow the network accessibility, size, geographical coverage and scope, to grow the portfolio of CTN supported studies (investigator initiated and industry studies), to develop a reputation for high quality work and establish a sustainable CTN for long term success.
We have an open and inclusive approach to requests for collaboration and assistance. In the CTN we aim to build collaborations for local and national investigator led studies and to develop industry collaborations into our portfolio.
ICC-CTN Supported Trials
Alistair Nichol presents the PHARLAP trial Results